• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Onconetix Inc.

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    SC 13G 1 ss4101599_sc13g.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     



     

    Onconetix, Inc.
    (Name of Issuer)

     

     

    Common stock, par value $0.00001 per share
    (Title of Class of Securities)

     

    68237Q104

    (CUSIP Number)

     

    September 24, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

             
    1

    NAME OF REPORTING PERSONS

     Zurcher Kantonalbank

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    562,691

    6 SHARED VOTING POWER
    7

    SOLE DISPOSITIVE POWER

     

     562,691

    8

    SHARED DISPOSITIVE POWER

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    562,691

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

       

     

     

     

    Item 1.   (a) Name of Issuer:
        Onconetix, Inc.

     

        (b) Address of Issuer’s Principal Executive Offices:

    201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202

     

    Item 2.   (a) Name of Person Filing:

    Zurcher Kantonalbank

        (b) Address of Principal Business Office:

    BAHNHOFSTRASSE 9

    ZURICH, SWITZERLAND 8001

        (c) Citizenship:

    Switzerland

        (d) Title of Class of Securities:

    Common stock, par value $0.00001 per share

        (e) CUSIP No.:

             68237Q104

     

    Item 3.      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

    Item 4. Ownership:

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     Not Applicable

     

     

    Item 9. Notice of Dissolution of Group.

     Not Applicable

       

     

     

     

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

       
           
      By: /s/ Matthias Nänni
        Name: Matthias Nänni
        Title: Senior Member of Management

     

     

       

     

     

     

    Get the next $ONCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

      CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company's request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing Rule 5550(a)(2) (the "Periodic Filing Listing Rule") by June 13, 2025 and the  Nasdaq Listing Rule 5250(c)(1) (the "Bid Price Listing Rule") on or before June 30, 2025. The

      6/16/25 8:22:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

      CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the "Special Meeting") held on May 30, 2025, and that its Board of Directors (the "Board of Directors" or "Board") approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 1

      6/11/25 11:30:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

      Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the "10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange C

      5/22/25 4:50:00 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care